NCCAM turns five
This article was originally published in The Tan Sheet
Executive Summary
National Center for Complementary & Alternative Medicine celebrates its fifth anniversary by announcing the launch of its second five-year strategic plan, NIH center says during recent advisory council meeting. Draft of the plan will be released in the fall. NCCAM director Stephen Straus, MD, cites the center's research portfolio containing "over 300 projects" and including the "largest ever placebo-controlled clinical trials of popular dietary supplements like glucosamine for degenerative arthritis and ginkgo biloba for dementia" among NCCAM's noteworthy accomplishments. Straus also notes that "most importantly, a body of data is emerging from NCCAM's investments in research that is informing public policy and helping guide practices"...
You may also be interested in...
CAM Research Should Test For Adverse Interactions – Toxicologist
Future research on complementary and alternative medicine should include clinical testing on interactions between dietary supplements and conventional medications, according to one toxicology expert
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.